PROceeding with the patient-reported outcomes (PROs) version of the common terminology criteria for adverse events

JAMA Oncology

Volumn 1, Issue 8, 2015, Pages 1059-1060

  Movsas, Benjamin ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; ADVERSE EFFECTS; CHEMORADIOTHERAPY; CLASSIFICATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MALE; NATIONAL HEALTH ORGANIZATION; NEOPLASMS; NOMENCLATURE; QUESTIONNAIRE; RADIATION INJURY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; RADIATION INJURIES; SURVEYS AND QUESTIONNAIRES; TERMINOLOGY AS TOPIC;

EID: 84964695039     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2689     Document Type: Note

References (5)

1. Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J Clin Oncol. 2014;32(26):2920-2927.
2. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103(24):1851-1858.
3. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [published online August 13, 2015]. JAMA Oncol.doi:10.1001/jamaoncol.2015.2639.
4. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
5. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288(23):3027-3034.